Skip to Content
Søg Menu

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

This article presents updated insights from the AVENANCE study about the role of avelumab in advanced urothelial carcinomas.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynækologisk cancer

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ BestPractice Nordic
ESMO24Gynækologisk cancer
Charlotte Aa. Hasund

ESMO 2024: Highlights for ovariecancer og endometricancer

/ Charlotte Haslund
ESMO24Gynækologisk cancer Play the Video 04:57
Mansoor Raza Mirza

ESMO 2024: Hope and Disappointment for Ovarian Cancer Treatment

/ Mansoor Raza Mirza
ESMO24Gynækologisk cancer Play the Video 09:55

ESMO24: New Standard of Care – Immunotherapy in High-Risk Locally Advanced Cervical Cancer

/ Jan Andreasen
ESMO24Gynækologisk cancer
Mansoor Raza Mirza

ESMO: Update on the ENGOT-EN6 RUBY Trial

/ Mansoor Raza Mirza
ESMO24Gynækologisk cancer Play the Video 02:46
Mansoor Raza Mirza

Mansoor Raza Mirza: ESMO is the Meeting Which Brings New Data for Forever Practice-Changing Trials

/ Mansoor Raza Mirza
ESMO24Gynækologisk cancer Play the Video 04:00
Simon Kreilgaard Buss

Topotecan er en sikker behandlingsform for patienter med platinresistent ovariecancer

/ Simon Kreilgaard Buss
DSKO24Gynækologisk cancer Play the Video 3:23
Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatacancer Play the Video 1:31

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top